<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979420</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1535</org_study_id>
    <nct_id>NCT00979420</nct_id>
  </id_info>
  <brief_title>Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune</brief_title>
  <official_title>Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The question that prompted this study is the extent to which results from clinical trials can
      be translated into everyday practice (external validity). An observation period of about 10
      years extends far beyond the duration of clinical trials. First and foremost are questions
      about tolerability and the efficacy of an antiretroviral combination treatment with Viramune
      and other antiretroviral partners. In particular, adverse events will be recorded and the
      therapeutic effect will be monitored via the course of viral load and improvement of the
      immune system, based on the CD4 cell count.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      observational
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in log10 Viral Load From Baseline to Last Visit</measure>
    <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
    <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available visit viral load minus the baseline viral load.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Viral Load &lt;50 Copies/ml and &gt;=50 Copies/ml at Last Visit</measure>
    <time_frame>Last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit</measure>
    <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
    <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Absolute CD4 Lymphocytes (CD4+ Cells) From Baseline to Last Visit</measure>
    <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
    <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Cholesterol During Study (Worst Grade) by Division of AIDS (DAIDS) Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (&quot;DAIDS AE Grading Table&quot;) was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Low-density Lipoprotein (LDL) Cholesterol During Study (Worst Grade) by DAIDS Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Triglycerides During Study (Worst Grade) by DAIDS Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Blood Glucose During Study (Worst Grade) by DAIDS Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Alanine Aminotransferase (ALT) During Study (Worst Grade) by DAIDS Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Aspartate Aminotransferase (AST) During Study (Worst Grade) by DAIDS Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Creatinine During Study (Worst Grade) by DAIDS Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Laboratory Abnormalities for Hemoglobin During Study (Worst Grade) by DAIDS Grade</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intake of Viramune</measure>
    <time_frame>End of treatment, up to 185 months</time_frame>
    <description>Duration of intake of Viramune</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of Therapy With Antiretroviral Medication</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants with a history of therapy with antiretroviral medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of Absolute CD4+ Cell Count</measure>
    <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months</time_frame>
    <description>The course of absolute CD4+ cell count is presented as the absolute CD4+ cell count at last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug Related Adverse Events</measure>
    <time_frame>Up to 185 months</time_frame>
    <description>Number of participants with drug related Adverse Events (AEs)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV treatment</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria The inclusion criteria for treatment with Viramune plus other
        antiretroviral combination drugs are to be based on the current Information for Healthcare
        Professionals/SPC (R08-0843)

        Exclusion criteria The exclusion criteria for treatment with Viramune plus other
        antiretroviral combination drugs are to be based on the current Information for Healthcare
        Professionals/SPC (R08-0843).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 10</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 11</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 12</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 13</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 14</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 15</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 5</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 6</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 7</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 8</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 9</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 16</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 17</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 18</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 19</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 20</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 21</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 22</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 23</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 24</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 25</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 26</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 27</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 28</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 29</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 30</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 31</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 32</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 33</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 34</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 35</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 36</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 37</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 38</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 39</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 40</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 41</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 42</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 43</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 44</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 45</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 46</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 47</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 48</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 49</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 50</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 51</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 52</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 53</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 54</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 55</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 56</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 57</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 58</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 59</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 60</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>May 30, 2012</results_first_submitted>
  <results_first_submitted_qc>July 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2012</results_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment-naive Patients</title>
          <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
        </group>
        <group group_id="P2">
          <title>Pre-treated Patients With Baseline HIV RNA &lt;50 Copies/ml</title>
          <description>HIV RNA denotes Human immunodeficiency virus (HIV) Ribonucleic acid (RNA). Baseline reflects the last available documentation before start of treatment with Viramune</description>
        </group>
        <group group_id="P3">
          <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
          <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
        </group>
        <group group_id="P4">
          <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
          <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons not related to Viramune</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set - all patients receiving at least one dose of study medication</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment-naive Patients</title>
          <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
        </group>
        <group group_id="B2">
          <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
          <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
        </group>
        <group group_id="B3">
          <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
          <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
        </group>
        <group group_id="B4">
          <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
          <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="178"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="61"/>
            <count group_id="B5" value="356"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.85" spread="10.54"/>
                    <measurement group_id="B2" value="54.21" spread="10.42"/>
                    <measurement group_id="B3" value="51.02" spread="7.66"/>
                    <measurement group_id="B4" value="53.69" spread="11.05"/>
                    <measurement group_id="B5" value="51.91" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in log10 Viral Load From Baseline to Last Visit</title>
        <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available visit viral load minus the baseline viral load.</description>
        <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
        <population>Full analysis set (FAS): This patient set includes all patients from Treated Set (TS) who have documented at least one value for the viral load before start of therapy with Viramune.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Change in log10 Viral Load From Baseline to Last Visit</title>
          <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available visit viral load minus the baseline viral load.</description>
          <population>Full analysis set (FAS): This patient set includes all patients from Treated Set (TS) who have documented at least one value for the viral load before start of therapy with Viramune.</population>
          <units>log10 copies/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.260" spread="-5.61;2.25" lower_limit="-5.61" upper_limit="2.25"/>
                    <measurement group_id="O2" value="-0.099" spread="-1.69;0.70" lower_limit="-1.69" upper_limit="0.70"/>
                    <measurement group_id="O3" value="-2.082" spread="-5.82;0.40" lower_limit="-5.82" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Viral Load &lt;50 Copies/ml and &gt;=50 Copies/ml at Last Visit</title>
        <time_frame>Last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
        <population>FAS: This patient set includes all patients from TS who have documented at least one value for the viral load before start of therapy with Viramune.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Load &lt;50 Copies/ml and &gt;=50 Copies/ml at Last Visit</title>
          <population>FAS: This patient set includes all patients from TS who have documented at least one value for the viral load before start of therapy with Viramune.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;50 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit</title>
        <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.</description>
        <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
        <population>FAS: This patient set includes all patients from TS who have documented at least one value for the viral load before start of therapy with Viramune.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit</title>
          <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.</description>
          <population>FAS: This patient set includes all patients from TS who have documented at least one value for the viral load before start of therapy with Viramune.</population>
          <units>CD4+ cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380" spread="-323;1749" lower_limit="-323" upper_limit="1749"/>
                    <measurement group_id="O2" value="223.5" spread="-328;1104" lower_limit="-328" upper_limit="1104"/>
                    <measurement group_id="O3" value="228" spread="-360;1004" lower_limit="-360" upper_limit="1004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in log10 Viral Load From Baseline to Last Visit</title>
        <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available visit viral load minus the baseline viral load.</description>
        <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
        <population>Per protocol set (PPS): All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Change in log10 Viral Load From Baseline to Last Visit</title>
          <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available visit viral load minus the baseline viral load.</description>
          <population>Per protocol set (PPS): All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years.</population>
          <units>log10 copies/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.284" spread="-5.61;0.00" lower_limit="-5.61" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.000" spread="-0.41;0.70" lower_limit="-0.41" upper_limit="0.70"/>
                    <measurement group_id="O3" value="-2.000" spread="-5.824;0.40" lower_limit="-5.824" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Viral Load &lt;50 Copies/ml and &gt;=50 Copies/ml at Last Visit</title>
        <time_frame>Last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
        <population>PPS: All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Load &lt;50 Copies/ml and &gt;=50 Copies/ml at Last Visit</title>
          <population>PPS: All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;50 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Absolute CD4 Lymphocytes (CD4+ Cells) From Baseline to Last Visit</title>
        <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.</description>
        <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.</time_frame>
        <population>PPS: All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute CD4 Lymphocytes (CD4+ Cells) From Baseline to Last Visit</title>
          <description>Baseline is defined as the last documentation before start of therapy with Viramune. The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.</description>
          <population>PPS: All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years.</population>
          <units>CD4+ cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392" spread="-323;1027" lower_limit="-323" upper_limit="1027"/>
                    <measurement group_id="O2" value="283" spread="-234;1104" lower_limit="-234" upper_limit="1104"/>
                    <measurement group_id="O3" value="250" spread="-266;987" lower_limit="-266" upper_limit="987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Cholesterol During Study (Worst Grade) by Division of AIDS (DAIDS) Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (&quot;DAIDS AE Grading Table&quot;) was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of cholesterol.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Cholesterol During Study (Worst Grade) by Division of AIDS (DAIDS) Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (&quot;DAIDS AE Grading Table&quot;) was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of cholesterol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Low-density Lipoprotein (LDL) Cholesterol During Study (Worst Grade) by DAIDS Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of LDL cholesterol.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Low-density Lipoprotein (LDL) Cholesterol During Study (Worst Grade) by DAIDS Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of LDL cholesterol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Triglycerides During Study (Worst Grade) by DAIDS Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of triglycerides.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Triglycerides During Study (Worst Grade) by DAIDS Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of triglycerides.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Blood Glucose During Study (Worst Grade) by DAIDS Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of blood glucose</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Blood Glucose During Study (Worst Grade) by DAIDS Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of blood glucose</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Alanine Aminotransferase (ALT) During Study (Worst Grade) by DAIDS Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of ALT</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Alanine Aminotransferase (ALT) During Study (Worst Grade) by DAIDS Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of ALT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Aspartate Aminotransferase (AST) During Study (Worst Grade) by DAIDS Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of AST</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Aspartate Aminotransferase (AST) During Study (Worst Grade) by DAIDS Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of AST</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Creatinine During Study (Worst Grade) by DAIDS Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of Creatinine.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Creatinine During Study (Worst Grade) by DAIDS Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of Creatinine.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Laboratory Abnormalities for Hemoglobin During Study (Worst Grade) by DAIDS Grade</title>
        <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of Hemoglobin.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA&lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Abnormalities for Hemoglobin During Study (Worst Grade) by DAIDS Grade</title>
          <description>Duration of intake of Viramune ranges from 14 to 185 months. The &quot;DAIDS AE Grading Table&quot; was used for grading the safety laboratory parameters. Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.</description>
          <population>Patients from Treated set (TS, all patients receiving at least one dose of study medication) with at least one documentation of Hemoglobin.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Intake of Viramune</title>
        <description>Duration of intake of Viramune</description>
        <time_frame>End of treatment, up to 185 months</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA &lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Intake of Viramune</title>
          <description>Duration of intake of Viramune</description>
          <population>Treated set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="30" upper_limit="185"/>
                    <measurement group_id="O2" value="124" lower_limit="43" upper_limit="149"/>
                    <measurement group_id="O3" value="131" lower_limit="14" upper_limit="159"/>
                    <measurement group_id="O4" value="129" lower_limit="105" upper_limit="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>History of Therapy With Antiretroviral Medication</title>
        <description>Participants with a history of therapy with antiretroviral medication.</description>
        <time_frame>Baseline</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA &lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>History of Therapy With Antiretroviral Medication</title>
          <description>Participants with a history of therapy with antiretroviral medication.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Course of Absolute CD4+ Cell Count</title>
        <description>The course of absolute CD4+ cell count is presented as the absolute CD4+ cell count at last visit.</description>
        <time_frame>Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months</time_frame>
        <population>PPS: All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA &lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Course of Absolute CD4+ Cell Count</title>
          <description>The course of absolute CD4+ cell count is presented as the absolute CD4+ cell count at last visit.</description>
          <population>PPS: All patients from FAS without treatment interruptions and who are treated with Viramune for at least 10 years</population>
          <units>CD4+ cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734" lower_limit="96" upper_limit="1526"/>
                    <measurement group_id="O2" value="669" lower_limit="189" upper_limit="1479"/>
                    <measurement group_id="O3" value="491" lower_limit="237" upper_limit="1326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug Related Adverse Events</title>
        <description>Number of participants with drug related Adverse Events (AEs)</description>
        <time_frame>Up to 185 months</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patient was not treated with any antiretroviral drugs (ARV) before start of therapy with Viramune</description>
          </group>
          <group group_id="O2">
            <title>Pre-treated Patients With Baseline HIV RNA &lt;50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O3">
            <title>Pre-treated Patients With Baseline HIV RNA&gt;=50 Copies/ml</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
          <group group_id="O4">
            <title>Pre-treated Patients With Baseline HIV RNA Not Documented</title>
            <description>Baseline reflects the last available documentation before start of treatment with Viramune</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug Related Adverse Events</title>
          <description>Number of participants with drug related Adverse Events (AEs)</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 to 185 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Viramune</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

